Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CTSV | O60911 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 3/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7244637 | 0.97 | CTSV (0.41) | KMT2AMEN1MAPTCTSVCTSL | |
| SCHEMBL7042572 | 0.94 | KMT2A (0.44) | KMT2AMEN1MAPTCTSVCTSL | |
| SCHEMBL7040318 | 0.93 | CTSV (0.40) | KMT2AMEN1MAPTCTSVCTSL | |
| SCHEMBL7044399 | 0.93 | CTSV (0.40) | KMT2AMEN1MAPTCTSVCTSL | |
| SCHEMBL7037727 | 0.92 | GAA (0.43) | KMT2AMEN1MAPTCTSVCTSL | |
| SCHEMBL7037102 | 0.89 | MAPT (0.39) | KMT2AMEN1MAPTMAOBALDH1A1 | |
| SCHEMBL6539571 | 0.88 | GAA (0.50) | KMT2AMEN1MAPTMAOBALDH1A1 | |
| SCHEMBL7039802 | 0.87 | MEN1 (0.41) | KMT2AMEN1MAPTCTSVCTSL | |
| SCHEMBL7246404 | 0.85 | BCHE (0.44) | KMT2AMEN1MAPTCTSVCTSL | |
| SCHEMBL7039495 | 0.85 | ALDH1A1 (0.40) | KMT2AMEN1MAPTABCB1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073846-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-04-17 | — | — | US | disclosed |
| EP-1292564-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001062705-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073846-A1 | Aminoalcohol derivatives | XDH, ADH1A, ADRB1 | KMT2A 1035/4885MEN1 2582/4885MAPT 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.